Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 8:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 479 matching trials from the live ClinicalTrials.gov search.
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Gatorade/Miralax With or Without Bisacodyl Versus NuLytely for Colonoscopy Preparation

NCT01063049
Conditions
Preparation for Colonoscopy
Interventions
Gatorade/Miralax, NuLytely, Bisacodyl, Placebo
Drug
Lead sponsor
Gastroenterology Services, Ltd.
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Downers Grove, Illinois
Conditions
Submental Fat
Interventions
10XB-101 Solution for Injection
Drug
Lead sponsor
10xBio, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Diego, California
Conditions
Rheumatoid Arthritis
Interventions
Cimzia, Placebo
Drug
Lead sponsor
Michael Schiff, MD
Individual
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more
Conditions
Prosthetic Joint Infection of Knee
Interventions
Intervention 1: Alternating Magnetic Field Treatment, Intervention 2 - Sham Treatment, Debridement, Antibiotics, Implant Retention
Device · Procedure
Lead sponsor
Solenic Medical, Inc.
Industry
Eligibility
22 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
New Albany, Ohio • Tulsa, Oklahoma
Conditions
Leukemia, Precursor-B Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Lymphoma
Interventions
Cytarabine, Daunorubicin, Vincristine, Prednisone, PEG asparaginase, Ofatumumab, Rituximab, Methotrexate, Cyclophosphamide, Mercaptopurine, Doxorubicin, Dexamethasone acetate, Thioguanine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hemophilia A
Interventions
PEGylated Recombinant Factor VIII, ITI
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 5 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Cupertino, California • Oakland, California + 17 more
Completed No phase listed Observational Results available

Lipids, Inflammation, and CV Risk in RA

NCT02714881
Conditions
Rheumatoid Arthritis, Cardiovascular Disease
Interventions
Certolizumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
35 Years to 90 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Crohn Disease
Interventions
Cimzia
Biological
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
20
States / cities
Lakewood, Colorado • Littleton, Colorado • New Port Richey, Florida + 16 more
Conditions
Dry Eye
Interventions
Systane Ultra Lubricant Eye Drops, Optive Lubricant Eye Drops, Blink Tears, GenTeal Moderate Lubricant Eye Drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Rheumatoid Arthritis, Osteoarthritis, Post-traumatic Arthritis, Avascular Necrosis
Interventions
Alumina/Alumina, Standard
Device
Lead sponsor
Encore Medical, L.P.
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
3
States / cities
Newport Beach, California • Charleston, South Carolina • Richmond, Virginia
Conditions
B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Interventions
L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, cytarabine, prednisone, bortezomib, pegaspargase, methotrexate, etoposide phosphate, cyclophosphamide, filgrastim, leucovorin calcium, laboratory biomarker analysis, High Dose MTX
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 31 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
157
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 124 more
Conditions
Line Insertion Site, Central Line-associated Bloodstream Infection (CLABSI)
Interventions
Povidone-Iodine, Chlorhexidine gluconate, Pluronic Cream, control
Drug · Other
Lead sponsor
University of Virginia
Other
Eligibility
Up to 7 Days
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Completed Phase 4 Interventional Results available

Prophylaxis Regimen for Hemophilia A Patients

NCT05036278
Conditions
Hemophilia A, Prophylaxis of Bleeding
Interventions
Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).
Biological
Lead sponsor
Bayer
Industry
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Loma Linda, California • Los Angeles, California • Aurora, Colorado + 8 more
Conditions
Constipation
Interventions
PEG 3350, PEG-3350 with electrolytes, Glycerin
Drug
Lead sponsor
Indiana University
Other
Eligibility
2 Years to 18 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2605541 in Healthy Participants

NCT01877265
Conditions
Healthy Volunteers
Interventions
LY2605541
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Los Angeles, California • Walnut Creek, California • Wheaton, Maryland + 3 more
Conditions
Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions
Pevonedistat, Vincristine, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Hydrocortisone
Drug
Lead sponsor
Julio Barredo, MD
Other
Eligibility
16 Years to 39 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Miami, Florida
Conditions
Metastatic Gastrointestinal Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Regional Gastrointestinal Carcinoid Tumor
Interventions
PEG-interferon alfa-2b, bevacizumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Conditions
Ankylosing Spondylitis
Interventions
Bimekizumab, Certolizumab pegol, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Ormond Beach, Florida • Lincoln, Nebraska • Oklahoma City, Oklahoma + 1 more
Conditions
Colonoscopy
Interventions
lubiprostone (Amitiza), Placebo
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
Detroit, Michigan • Novi, Michigan • West Bloomfield, Michigan
Conditions
Varicose Veins
Interventions
Varithena®, FDA-approved Endothermal Ablation (ETA) systems
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Darien, Connecticut • Washington D.C., District of Columbia • Houma, Louisiana + 6 more
Conditions
Crohn's Disease
Interventions
Fluconazole, Vancomycin, Neomycin, Ciprofloxacin, Polyethylene Glycol 3350, Promethazine, Fluconazole placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 3 Interventional Results available

EZN-2279 in Patients With ADA-SCID

NCT01420627
Conditions
ADA-SCID, Adenosine Deaminase Deficiency, Severe Combined Immunodeficiency
Interventions
EZN-2279, Adagen
Biological
Lead sponsor
Leadiant Biosciences, Inc.
Industry
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 3 more
Conditions
Dry Eye Syndrome
Interventions
Cyclosporin A Restasis®, Blink tears, Systane
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Charleston, South Carolina